Biological agents (Etanercept, Infliximab and adalimumab) targeting TNF- α have showed high efficacy in psoriasis therapy, which consists with the pivotal role of TNF- α in the pathogenesis of psoriasis. The gene discussed is TNF; the disease is psoriasis.